87 related articles for article (PubMed ID: 19912209)
1. Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.
Jankun J; Selman SH; Keck RW; Łysiak-Szydłowska W; Skrzypczak-Jankun E
BJU Int; 2010 May; 105(10):1469-76. PubMed ID: 19912209
[TBL] [Abstract][Full Text] [Related]
2. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
3. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.
Jankun J; Keck R; Selman SH; Skrzypczak-Jankun E
Int J Mol Med; 2010 Oct; 26(4):501-4. PubMed ID: 20818488
[TBL] [Abstract][Full Text] [Related]
4. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
5. Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
Shahrour K; Keck R; Jankun J
Biomed Res Int; 2015; 2015():392862. PubMed ID: 25883959
[TBL] [Abstract][Full Text] [Related]
6. Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life.
Jankun J; Aleem AM; Struniawski R; Lysiak-Szydłowska W; Selman SH; Skrzypczak-Jankun E
Pharmacol Rep; 2009; 61(4):673-80. PubMed ID: 19815949
[TBL] [Abstract][Full Text] [Related]
7. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
Jankun J; Yang J; Zheng H; Han FQ; Al-Senaidy A; Skrzypczak-Jankun E
Int J Mol Med; 2012 Jan; 29(1):61-4. PubMed ID: 21947232
[TBL] [Abstract][Full Text] [Related]
8. Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.
Kindell DG; Keck RW; Jankun J
Exp Ther Med; 2015 Jun; 9(6):2339-2343. PubMed ID: 26136983
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients.
Jankun J; Skrzypczak-Jankun E
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):144-50. PubMed ID: 23988002
[TBL] [Abstract][Full Text] [Related]
10. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
[TBL] [Abstract][Full Text] [Related]
11. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
[TBL] [Abstract][Full Text] [Related]
13. Short-term effect of surgical trauma on rat peritoneal fibrinolytic activity and its role in adhesion formation.
Hellebrekers BW; Trimbos-Kemper GC; Bakkum EA; Trimbos JB; Declerck PJ; Kooistra T; Emeis JJ
Thromb Haemost; 2000 Nov; 84(5):876-81. PubMed ID: 11127871
[TBL] [Abstract][Full Text] [Related]
14. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
15. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
16. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
17. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
18. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
[TBL] [Abstract][Full Text] [Related]
19. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
[TBL] [Abstract][Full Text] [Related]
20. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
